OSTM1 and osteopetrosis: OSTM1 (osteopetrosis-associated transmembrane protein 1) mutations are reported in 5% of ARO cases (4, 22, 23) and invariably cause osteopetrosis and severe primary neurodegeneration, with a life expectancy lower than 2 years (22, 24–26).